Carter Todd Alfred 4

What Happened

• Carter Todd Alfred, Chief Scientific Officer of Voyager Therapeutics, sold 3,301 shares of Voyager common stock on 2026-02-18. The reported weighted-average price was $3.44 per share, for total proceeds of approximately $11,355. This was a sale (not a purchase) and was executed to satisfy tax withholding obligations following the vesting of restricted stock units.

Key Details

• Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (appears timely; Form 4s are due within two business days).
• Transaction type/code: Open-market/private sale (Code S). Footnote indicates the sales were automatic sell-to-cover instructions (not a discretionary trade).
• Price: weighted average $3.44; shares sold across prices ranging $3.40–$3.47 (reporting person can provide per-price breakdown on request).
• Shares owned after transaction: Not disclosed in the excerpt of the filing provided.
• Footnotes/remarks: F1 — sale pursuant to durable automatic sale instruction to satisfy tax withholding for RSU vesting; F2 — weighted-average price and price range; Exhibit 24.1 registers a Limited Power of Attorney.

Context

• These shares were sold as a routine sell-to-cover to cover taxes on vested RSUs, which the filing explicitly notes were not discretionary trades by the insider. Such tax-withholding sales are common and generally not taken as a signal of management sentiment; purchases are typically more informative about insider confidence.